ETON Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. (ETON) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $2.3M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| CASAMENTO CHARLES J 5 fills | Director | Sell | 80,555 | $66.35 | $5.3M | 74,175 −52.1% of holding | |
| Erdogan-Trinkaus Ipek 2 fills | Chief Commercial Officer | Sell | 3,500 | $67.41 | $235.9K | 5,241 −40% of holding | |
| Krempa David | Chief Business Officer | Sell | 4,166 | $55.07 | $229.4K | 43,381 −8.8% of holding | |
| MAIER PAUL V 6 fills | Director | Sell | 100,000 | $59.07 | $5.9M | 73,358 −57.7% of holding | |
| Krempa David | Chief Business Officer | Sell | 25,000 | $65.07 | $1.6M | 37,025 −40.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.